Why Owner-Rated Mobility Scores Matter
Canine osteoarthritis (OA) is one of the most under-recognised conditions in older dogs. The published VetCompass UK epidemiology puts prevalence around 2.5% of all dogs and 20%+ of dogs over 8 years — but those are *diagnosed* cases. Hidden OA is far more common. Owners often interpret early signs (“slowing down”, “less interested in walks”) as ageing rather than pain.
Owner-rated mobility scoring changes that. A structured 10-item assessment captures change that day-to-day observation misses, and a few weeks of repeated scoring shows whether treatment is working. The construct used here is based on the published validated instruments — LOAD (Liverpool Osteoarthritis in Dogs, Hercock 2009), HCPI (Helsinki Chronic Pain Index, Hielm-Björkman 2003) and the CBPI mobility section (Canine Brief Pain Inventory, Brown 2007). We implement the same construct with our own wording while crediting these scientific contributions.
The Ten Domains
| Item | What it captures |
|---|---|
| Rising from rest | Joint pain peaks after periods of immobility |
| Lying down | Inverse of rising – difficulty changing position |
| Stiffness after rest | Classic OA hallmark |
| Lameness / limping | Direct mobility impairment |
| Activity tolerance on walks | Functional cardiovascular + mobility marker |
| Willingness to play | Often the first sign to drop |
| Stairs / jumping | Loading and propulsion tests |
| Difficulty after exercise | Captures delayed pain – sometimes the most useful item |
| Quality of sleep | Pain disrupts sleep, restless sleep predicts pain |
| Overall mood / engagement | Dogs in chronic pain become quieter |
Each scored 0 (no problem) to 4 (severe problem), summed to /40.
The Score Tiers
| Total | Tier | Action |
|---|---|---|
| 0-5 | Minimal / Mild | Maintenance care; lean body, omega-3, controlled exercise |
| 6-15 | Moderate | Engage vet; baseline NSAID + nutritional therapy + physio |
| 16-25 | Marked | Optimise multimodal therapy: Librela, gabapentin, intra-articular options |
| 26-40 | Severe | Vet visit within days; aggressive multimodal pain management |
What the Modern Multimodal Toolkit Looks Like
OA management has changed dramatically in the past 5 years. The current evidence base supports a layered approach:
Foundation (every OA dog)
- Lean body condition (BCS 4-5) — the Kealy 2002 Purina Life Span Study showed lean-fed Labradors had measurably less OA, later onset, and 1.8 years longer median lifespan. Weight loss in already-overweight OA dogs has well-documented mobility benefit even before drug therapy.
- Controlled exercise — daily, predictable, low-impact. Avoid “weekend warrior” bursts that flare up joints.
- Omega-3 (EPA + DHA) at therapeutic doses — multiple RCTs show modest but real benefit at combined EPA+DHA around 90-100 mg/kg/day.
- Joint diet — Hill’s j/d and Royal Canin Mobility are RCT-validated complete foods.
NSAID (most moderate-to-marked OA)
- Carprofen (Rimadyl), meloxicam (Loxicom), firocoxib (Previcox) — long-standing, very effective for OA in dogs.
- Galliprant (grapiprant) — a newer COX-2/EP4 selective with a different safety profile, useful in older dogs with renal concerns.
- Always with baseline bloods (renal + hepatic) before starting and every 6 months on therapy.
Anti-NGF monoclonal antibody
- Librela / bedinvetmab — a once-monthly subcutaneous injection that binds nerve growth factor and has transformed OA care for many older dogs. RCTs show meaningful efficacy with a clean side-effect profile. Particularly useful when NSAIDs cannot be used or when more pain relief is needed than NSAID alone provides.
Adjuncts for breakthrough or neuropathic pain
- Gabapentin or pregabalin — particularly useful for evening/nighttime pain.
- Amantadine — NMDA antagonist for centrally-sensitised pain.
- Tramadol — variable efficacy in dogs; generally not first-line.
Intra-articular options
- Hyaluronate injection
- Platelet-rich plasma (PRP) — emerging evidence
- Stem cell therapy — investigational
Surgical
- Total hip replacement for hip dysplasia with severe OA — excellent outcomes
- TPLO / TTA for cranial cruciate disease
- Femoral head ostectomy (FHO) for small dogs with hip OA
Environmental optimisation
Often the highest-impact intervention per pound spent:
- Non-slip flooring — rugs, runners, vinyl strips
- Ramps for cars, furniture, bed
- Raised feeding stands
- Orthopaedic bedding (not pillow-soft sofas)
- Harness with a back handle to help stand
Physiotherapy / Hydrotherapy
Strong evidence base. Specialist veterinary physiotherapy and hydrotherapy pools can transform mobility in moderate-to-marked OA dogs.
Tracking Response
Re-score every 4-6 weeks, and after any major management change. A 25-30% drop in total score is generally considered a meaningful clinical response. If a new therapy has not produced that within 6-8 weeks, it is reasonable to escalate or substitute.
Breed-Specific Joint Predispositions
The calculator pulls breed-specific predispositions from the PuppaDogs breed database. Common patterns:
- Hip dysplasia: German Shepherd, Labrador, Golden Retriever, Rottweiler, Newfoundland, Bernese, Saint Bernard, English Bulldog
- Elbow dysplasia: Labrador, Golden, Rottweiler, German Shepherd, Newfoundland, Bernese
- Patellar luxation: Yorkshire Terrier, Pomeranian, Mini Poodle, Chihuahua, Boston Terrier
- Cranial cruciate disease: Labrador, Rottweiler, Boxer, Saint Bernard, Mastiff
- Intervertebral disc disease (IVDD): Dachshund, French Bulldog, Pekingese, Beagle, Welsh Corgi
- Osteochondritis dissecans (OCD): Large/giant breeds during growth
Breed-aware scoring matters because mobility problems in different breeds have very different causes. A 4-year-old Dachshund that suddenly cannot rise needs IVDD ruled out, not OA workup. A 10-year-old Labrador that slowly stops jumping into the car is much more likely OA.
Honest Caveats
- This is a score, not a diagnosis. Many other conditions cause mobility problems: spinal disease, neuropathy, soft-tissue injury, neoplasia, endocrine disease. A vet evaluation translates the score into a diagnosis.
- Owner ratings tend to be slightly more optimistic than vet ratings. The trend over multiple scores is more useful than any single value.
- Pain in dogs is subtle. A dog that is “still happy” and “still eats” can be in significant pain – dogs hide pain by behavioural quietening rather than overt distress.
- The 0-4 per item scale does not capture all clinically relevant variation. For a fuller assessment, ask your vet about a clinical examination plus radiographs of suspected joints.
Conclusion
Owner-rated mobility scoring is one of the most useful pieces of structured assessment a dog owner can do. This calculator implements a 10-item construct based on the published LOAD / HCPI / CBPI instruments, produces a severity tier with practical action steps, and customises by breed. Re-score every 4-6 weeks during treatment, target a 25-30% reduction in total score as evidence of meaningful response, and use the result to guide an active conversation with your vet about multimodal pain management.
Frequently Asked Questions
How do I know if my dog has arthritis?
The early signs are subtle and often dismissed as ‘just ageing’: slowing down on walks, reluctance to jump, stiffness after rest, difficulty rising, reduced play, restless sleep. Owners typically miss these for months. A structured 10-item mobility score (rising, lying, stiffness, lameness, walks, play, stairs, post-exercise, sleep, mood) captures the impact better than memory. Score above 5/40 warrants a vet conversation; above 15 warrants active multimodal treatment.
What is the LOAD score for dogs?
LOAD (Liverpool Osteoarthritis in Dogs) is the published 13-item owner-completed mobility scale developed by Hercock et al. 2009 at the University of Liverpool. It is widely used in canine OA research and clinical practice to assess severity and track response to treatment. This calculator implements a 10-item construct based on the same underlying domains (LOAD plus HCPI and CBPI) with original wording.
What is the best treatment for arthritis in dogs?
Modern OA management is multimodal: lean body condition (BCS 4-5), controlled exercise, omega-3 supplementation, joint diet, NSAIDs (carprofen / meloxicam / Galliprant), anti-NGF monoclonal antibody (Librela), adjunct gabapentin or pregabalin for neuropathic pain, environmental optimisation (non-slip floors, ramps, orthopaedic bedding), and physiotherapy / hydrotherapy. Surgical options including total hip replacement and TPLO exist for severely affected joints.
Is Librela worth it for my dog’s arthritis?
Librela (bedinvetmab) is a once-monthly anti-NGF monoclonal antibody that has transformed older-dog arthritis care. Randomised controlled trial evidence shows meaningful efficacy with a clean side-effect profile. It is particularly useful when NSAIDs cannot be used (kidney or liver concerns) or when more pain relief is needed than NSAID alone provides. Cost varies by region and dog size; many vets consider it among the most effective single tools available for marked-tier canine OA.
How often should I re-score my dog’s arthritis?
Re-score every 4-6 weeks during ongoing treatment, and after any major management change. A 25-30% drop in total score is generally considered a meaningful clinical response. If a new therapy has not produced that within 6-8 weeks, it is reasonable to escalate or substitute with vet input.
Does weight loss help arthritis in dogs?
Yes – very meaningfully. The Kealy 2002 Purina Life Span Study showed lean-fed Labradors had less OA, later onset, and 1.8 years longer median lifespan. Weight loss in already-overweight OA dogs produces measurable mobility benefit even before drug therapy. Even 6-15% weight loss has documented effect in published RCTs. Lean body condition (BCS 4-5) is the single best long-term intervention for canine OA.
References & Further Reading
The dosing ranges and safety information on this page are drawn from the following veterinary references. Always defer to your own veterinarian and the manufacturer’s label for your specific product.
- Hercock CA, Pinchbeck G, Giejda A, et al. Validation of a client-based clinical metrology instrument for the evaluation of canine elbow osteoarthritis. Journal of Small Animal Practice, 2009 – the LOAD score.
- Hielm-Bjorkman AK, Kuusela E, Liman A, et al. Evaluation of methods for assessment of pain associated with chronic osteoarthritis in dogs. JAVMA, 2003 – the Helsinki Chronic Pain Index (HCPI).
- Brown DC, Boston RC, Coyne JC, Farrar JT. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. AJVR, 2007 – the Canine Brief Pain Inventory (CBPI).
- Kealy RD, Lawler DF, Ballam JM, et al. Effects of diet restriction on life span and age-related changes in dogs. JAVMA, 2002 – lean body condition + 1.8 years; less OA.
- Lascelles BDX, Knazovicky D, Case B, et al. A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility in dogs with chronic osteoarthritis. Frontiers in Veterinary Science, 2015 – Librela / bedinvetmab evidence.
- WSAVA Global Pain Council. Guidelines for Recognition, Assessment and Treatment of Pain. 2014. wsava.org.
- PuppaDogs. Librela Dosage Calculator and Galliprant Dosage Calculator. puppadogs.com.
